Konference: 2007 49th ASH Annual Meeting - účast ČR
Kategorie:
Maligní lymfomy a leukémie
Téma: Postery
Číslo abstraktu: 1830
Autoři: V. Balgobind Vrian; MD Iris H.I.M. Hollink, PhD; MD Dirk Reinhardt, PhD; Jutta Bradtke; Andrea Teigler-Schlegel, PhD; R. von Bergh Anne; Jacqueline Cloos, Ph.D.; MD Gertjan (J.L.) Kaspers, PhD; van Wering Elisabeth; Doc.RNDr. Zuzana Zemanová, CSc.; prof. MUDr. Jan Starý, DrSc.; Jean-Michel Cayuela, PhD.; MD Andre Baruchel, PhD; MD Marry M. van den Heuvel-Eibrink, PhD
Young children (defined as <2 years old) with acute myeloid
leukemia (AML) do not differ in outcome when compared with older
children with AML. Previously, distinct cytogenetic aberrations
specific for AML in young children have been reported, such as
t(7;12), and t(1;22), which is found exclusively in FAB M7.
Moreover, young children with AML are characterized by a high
frequency of 11q23-rearrangements. However, so far, no information
is available on differences in the molecular genetic background of
these two age groups. We therefore retrospectively investigated the
distribution of different cytogenetic and molecular aberrations in
a large cohort (n=435) of pediatric AML cases, of which 75 (17%)
were young children. The predominant cytogenetic aberration in
infant AML consisted of 11q23-rearrangements, which occurred in 44%
of young children versus 17% in older children (p=<0.005),
without differences in the distribution of 11q23-translocation
partners. We also found significant differences in other
cytogenetic subgroups of AML between young and older children, i.e.
normal karyotype, 5% vs. 18%, respectively (p=0.008) and complex
karyotype, 12% vs. 5% (p=0.03). t(7;12) (n=3) and t(8;16) (n=3)
were only detected in young children, in contrast to t(15;17)
(n=16) and t(8;21) (n=44), which were only seen in older children.
Patients were also screened for molecular abnormalities, including
the mutational hotspots of c-KIT (n=229), FLT3 (n=230), N-RAS
(n=187), K-RAS (n=187), PTPN11 (n=216), MLL-partial tandem
duplications (MLL-PTD) (n=240) and NPM1 (n=291). In the overall
cohort, a significantly different age distribution was found for
NPM1 mutations (0% young vs. 9% in older children; p=0.05) and
FLT3-ITD (0% vs. 21%, respectively; p=0.005). Mutations in the
other genes showed no clear correlation with age. Several
non-random associations between molecular and cytogenetic
abnormalities were detected. 89% of c-KIT mutations were associated
with core-binding factor AML in children 2 years old. In young
children, 2/4 c-KIT-mutated cases were associated with an
MLL-rearrangement. NPM1 and FLT3-ITD mutations in older children
were significantly correlated with normal karyotype AML (57% of
NPM1 mutations, and 75% of FLT3/ITD; p=<0.005). In young
children, 71% of RAS mutations were associated with an
11q23-rearrangement vs. 28% in older children (p=0.08). In older
children however, 41% of the RAS mutations were associated with a
normal karyotype. These data suggest that young children with AML
are characterized by differences in the type and frequency of
cytogenetic and molecular genetic abnormalities when compared with
older children with AML, possibly reflecting differences in
underlying biology between these age-groups. These differences may
become clinically relevant in the era of molecularly targeted
therapy.
Abstract #1830 appears in Blood, Volume 110, issue 11, November 16,
2007
Keywords: Pediatric|Cytogenetic Abnormalities|Molecular
Markers
Disclosure: No relevant conflicts of interest to declare.
Sunday, December 9, 2007 6:00 PM
Session Info: Poster Session: Acute Myeloid Leukemia: Biology and
Pathophysiology II (6:00 p.m.-8:00 p.m.)
Datum přednesení příspěvku: 9. 12. 2007